{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:14:04Z","timestamp":1780920844346,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373052"],"award-info":[{"award-number":["82373052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101153","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:04:57Z","timestamp":1771952697000},"page":"101153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Conversion treatment with hepatic arterial infusion of oxaliplatin, leucovorin and fluorouracil plus intravenous bevacizumab or cetuximab for initially unresectable colorectal liver metastasis: A prospective study"],"prefix":"10.1016","volume":"47","author":[{"given":"Wei","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101153_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101153_bib0002","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101153_bib0003","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes","volume":"261","author":"D\u02bcAngelica","year":"2015","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101153_bib0004","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101153_bib0005","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/SLA.0000000000001475","article-title":"Early and long-term oncological outcomes after laparoscopic resection for colorectal liver metastases: a propensity score-based analysis","volume":"262","author":"Allard","year":"2015","journal-title":"Ann. Surg."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101153_bib0006","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamasurg.2019.1694","article-title":"Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review","volume":"154","author":"Datta","year":"2019","journal-title":"JAMA Surg."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101153_bib0007","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jso.21393","article-title":"Role of the surgeon as a variable in long-term survival after liver resection for colorectal metastases","volume":"100","author":"Giuliante","year":"2009","journal-title":"J. Surg. Oncol."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101153_bib0008","doi-asserted-by":"crossref","first-page":"8198","DOI":"10.1245\/s10434-021-10220-w","article-title":"Liver-first approach for synchronous colorectal metastases: analysis of 7360 patients from the LiverMetSurvey registry","volume":"28","author":"Giuliante","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101153_bib0009","doi-asserted-by":"crossref","first-page":"11645","DOI":"10.2147\/OTT.S271955","article-title":"Emerging role of immunotherapy for colorectal cancer with liver metastasis","volume":"13","author":"Yu","year":"2020","journal-title":"Onco Targets. Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101153_bib0010","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1245\/s10434-011-2061-0","article-title":"A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases","volume":"19","author":"Lam","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101153_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123535","article-title":"Perioperative chemotherapy for liver metastasis of colorectal cancer","volume":"12","author":"Chan","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101153_bib0012","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101153_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113400","article-title":"Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: a multicenter phase II trial","volume":"195","author":"Malka","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"27","key":"10.1016\/j.ctarc.2026.101153_bib0014","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial","volume":"38","author":"Tang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101153_bib0015","article-title":"Meta-analysis of hepatic arterial infusion for liver metastases from colorectal cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101153_bib0016","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1007\/s00330-020-07253-2","article-title":"Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial","volume":"31","author":"Vogl","year":"2021","journal-title":"Eur. Radiol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101153_bib0017","first-page":"231","article-title":"Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: single centre experience","volume":"41","author":"Trivi\u00f1o-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Rev. Esp. Med. Nucl. Imagen. Mol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101153_bib0018","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","article-title":"Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer","volume":"23","author":"Ducreux","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101153_bib0019","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1097\/SLA.0000000000004613","article-title":"Distinct genomic profiles are associated with conversion to resection and survival in patients with initially unresectable colorectal liver metastases treated with systemic and hepatic artery chemotherapy","volume":"276","author":"Datta","year":"2022","journal-title":"Ann. Surg."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101153_bib0020","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2010.32.5977","article-title":"Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer","volume":"29","author":"Kemeny","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101153_bib0021","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1634\/theoncologist.2020-0563","article-title":"Modified FOLFOXIRI with or without Cetuximab as conversion therapy in patients with RAS\/BRAF wild-type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase ii trial","volume":"26","author":"Hu","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101153_bib0022","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4149\/neo_2023_230806N413","article-title":"Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial","volume":"70","author":"Liu","year":"2023","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101153_bib0023","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/SLA.0000000000005380","article-title":"A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic, or open liver resection for patients with BCLC stage 0-A hepatocellular carcinoma","volume":"277","author":"Zhu","year":"2023","journal-title":"Ann. Surg."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101153_bib0024","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s11605-018-3689-x","article-title":"Learning curve in robot-assisted laparoscopic liver resection","volume":"23","author":"Zhu","year":"2019","journal-title":"J. Gastrointest. Surg."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101153_bib0025","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1007\/s00464-017-5854-9","article-title":"Intraoperative ultrasonography of robot-assisted laparoscopic hepatectomy: initial experiences from 110 consecutive cases","volume":"32","author":"Zhu","year":"2018","journal-title":"Surg. Endosc."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101153_bib0026","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/01.sla.0000189131.90876.9e","article-title":"The \"50-50 criteria\" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy","volume":"242","author":"Balzan","year":"2005","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101153_bib0027","first-page":"7","article-title":"[Surgical anatomy of the liver and liver resection. Brisbane 2000 Terminology]","volume":"104","author":"Popescu","year":"2009","journal-title":"Chirurgia"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101153_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.2064","article-title":"Assessment of textbook outcome in laparoscopic and open liver surgery","volume":"156","author":"G\u00f6rgec","year":"2021","journal-title":"JAMa Surg."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101153_bib0029","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"L\u00e9vi","year":"2016","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101153_bib0030","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","article-title":"Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases","volume":"31","author":"Ye","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2d","key":"10.1016\/j.ctarc.2026.101153_bib0031","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101153_bib0032","doi-asserted-by":"crossref","first-page":"366","DOI":"10.6004\/jnccn.2024.0041","article-title":"NCCN Guidelines\u00ae insights: rectal cancer, version 3.2024","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101153_bib0033","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101153_bib0034","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/hpb.12159","article-title":"Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases","volume":"16","author":"Devaud","year":"2014","journal-title":"HPB"},{"issue":"18","key":"10.1016\/j.ctarc.2026.101153_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184434","article-title":"Survival evidence of local control for colorectal cancer liver metastases by hepatectomy and\/or radiofrequency ablation","volume":"15","author":"Canseco","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101153_bib0036","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14701\/ahbps.22-043","article-title":"Simultaneous resection of synchronous colorectal liver metastasis: feasibility and development of a prediction model","volume":"27","author":"Kazi","year":"2023","journal-title":"Ann. Hepatobiliary. Pancreat. Surg."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101153_bib0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamasurg.2020.5050","article-title":"Anterior approach vs conventional hepatectomy for resection of colorectal liver metastasis: a randomized clinical trial","volume":"156","author":"Rahbari","year":"2021","journal-title":"JAMa Surg."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101153_bib0038","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00384-021-04064-9","article-title":"Comparison of safety and efficacy of fluorouracil\u2009+\u2009oxaliplatin\u2009+\u2009irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice","volume":"37","author":"Kazama","year":"2022","journal-title":"Int. J. Colorectal. Dis."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101153_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004389","article-title":"Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS\/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): a randomized controlled trial","volume":"21","author":"Wang","year":"2024","journal-title":"PLoS. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101153_bib0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s12885-023-11085-w","article-title":"Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study - (NCT05103020) - study protocol","volume":"23","author":"Kim","year":"2023","journal-title":"BMC. Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101153_bib0041","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/bjs.9213","article-title":"Surgical management of disappearing colorectal liver metastases","volume":"100","author":"Bischof","year":"2013","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ctarc.2026.101153_bib0042","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2200598","article-title":"The influence of radiological \"disappearing lesions\" on the efficacy and prognosis of patients with colorectal liver metastases undergoing conversion therapy","volume":"2022","author":"Song","year":"2022","journal-title":"Gastroenterol. Res. Pract."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101153_bib0043","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.ejso.2016.05.005","article-title":"Management of disappearing colorectal liver metastases","volume":"42","author":"Kuhlmann","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101153_bib0044","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.hpb.2018.02.377","article-title":"Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography","volume":"20","author":"Oba","year":"2018","journal-title":"HPB"},{"key":"10.1016\/j.ctarc.2026.101153_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.suronc.2019.02.005","article-title":"Disappearing liver metastases: a systematic review of the current evidence","volume":"29","author":"Tsilimigras","year":"2019","journal-title":"Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101153_bib0046","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/gastro\/goab033","article-title":"The \"Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil, and leucovorin for colorectal cancer\"","volume":"9","author":"Deng","year":"2021","journal-title":"Gastroenterol. Rep."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101153_bib0047","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1245\/s10434-014-4228-y","article-title":"Concordance of carcinoembryonic antigen ratio and response evaluation criteria in solid tumors as prognostic surrogate indicators of metastatic colorectal cancer patients treated with chemotherapy","volume":"22","author":"Huang","year":"2015","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:54:56Z","timestamp":1780919696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422600064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"alternative-id":["S246829422600064X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101153","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conversion treatment with hepatic arterial infusion of oxaliplatin, leucovorin and fluorouracil plus intravenous bevacizumab or cetuximab for initially unresectable colorectal liver metastasis: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101153"}}